Skip to main content
Premium Trial:

Request an Annual Quote

LumiraDx Gets FDA Emergency Use Authorization for PCR-Based Coronavirus Test

NEW YORK — The US Food and Drug Administration last week granted Emergency Use Authorization for LumiraDx's SARS-CoV-2 RNA STAR Complete assay.

The PCR-based test is designed to detect a region in the SARS-CoV-2 ORF1a gene in upper respiratory specimens. According to Waltham, Massachusetts-based LumiraDx, it uses a non-isothermal nucleic acid amplification technique called qSTAR that does not require nucleic acid purification or extraction.

The assay runs on a range of PCR instruments including Roche's LightCycler 480 II, Thermo Fisher Scientific's Applied Biosystems 7500 Fast Dx and QuantStudio 5 systems, and Agilent's Aria Mx and Stratagene Mx3005P systems. Results are provided within 20 minutes, LumiraDx said.

The test may be used by any lab CLIA-certified to perform high-complexity tests, according to the FDA.

In August, LumiraDx received EUA from the FDA for the SARS-CoV-2 RNA STAR assay, which also detects the SARS-CoV-2 ORF1a gene but requires nucleic acid extraction. In addition, the company obtained EUA for a rapid antigen test that month.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.